NYSEAMERICAN:OGEN Oragenics Q3 2025 Earnings Report $0.47 -0.02 (-3.32%) Closing price 04:10 PM EasternExtended Trading$0.47 +0.00 (+0.51%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings History Oragenics EPS ResultsActual EPS-$1.96Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOragenics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOragenics Announcement DetailsQuarterQ3 2025Date11/7/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Oragenics Earnings HeadlinesOragenics (NYSEAMERICAN:OGEN) Shares Up 3.5% - Here's WhySeptember 25 at 2:01 AM | americanbankingnews.comOragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumSeptember 16, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 28 at 1:00 AM | Stansberry Research (Ad)Oragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateAugust 30, 2026 | finanznachrichten.deOragenics Faces NYSE Compliance Challenges Amid Trial ProgressAugust 28, 2026 | tipranks.comOragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing StatusAugust 28, 2026 | quiverquant.comQSee More Oragenics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email. Email Address About OragenicsOragenics (NYSEAMERICAN:OGEN) is a biotechnology company focused on developing intranasal medicines for diseases and conditions affecting the central nervous system. Its platform is designed to use the nasal cavity as a route for delivering therapeutic compounds to the brain, with the goal of improving treatment access and reducing barriers associated with conventional drug delivery. The company’s lead development program is ONP-002, an intranasal drug candidate being studied for the treatment of traumatic brain injury, including concussion. Oragenics has also pursued additional neuroscience and infectious-disease programs, although its research priorities and pipeline have evolved over time. Founded in 1996, Oragenics historically worked on oral-health products, probiotics and antibiotic technologies, including the development of lantibiotic compounds. The company is headquartered in Tampa, Florida, and its shares trade on the NYSE American under the symbol OGEN.View Oragenics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
